Baxter Debuts Dialysis that Clears Greater Range of Harmful Molecules
Monday, October 24, 2016
Baxter ($BAX) launched a new type of hemodialysis in a handful of countries, which uses a new dialyzer that filters a greater range of molecules from the blood, better simulating the function of a natural kidney.
Expanded hemodialysis, or HDx, is enabled by Baxter’s Theranova dialyzer, which is indicated for the treatment of acute and chronic renal failure, according to a statement. People with renal failure are unable to clear harmful molecules from their blood. Existing dialysis treatments effectively remove smaller middle molecules, such as urea, but tend not to be as effective with large middle molecules.
A recent study showed that Theranova was able to remove a broader range of middle molecules than other dialyzers on the market, including according to the statement. It involved 39 patients in Austria and Germany and examined the clearance of free immunoglobulin light chains by traditional dialysis, HDF--a type of dialysis that targets larger middle molecules--and Theranova.